Nefopam Medisol (Nefopam Hydrochloride)

Nefopam blocks the reuptake of serotonin, norepinephrine and dopamine and also inhibits sodium channels. This combination enhances descending inhibitory pathways and reduces neuronal excitability, producing analgesic effects without engaging opioid receptors.

The specific dose and frequency of Nefopam Medisol are determined by the prescribing clinician based on the patient’s condition, severity of pain, and route of administration. No standard dosing regimen is provided here.

Safety data for nefopam in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike opioids, nefopam is a non‑opioid analgesic that does not act on µ‑opioid receptors, reducing the risk of respiratory depression, dependence and constipation. Its mechanism involves monoamine reuptake inhibition and sodium‑channel blockade, offering an alternative for patients where opioids are contraindicated or undesirable.

Nefopam Medisol should be stored at ambient temperature, preferably below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct light, and ensure they are not exposed to extreme temperatures.

The product is supplied as an injectable solution for intramuscular or intravenous administration. Injection technique and site selection follow standard clinical practice, and the medication should be administered by qualified healthcare personnel.

Serious adverse events include seizures, severe hypotension, and allergic reactions such as rash, angioedema or anaphylaxis. Prompt medical attention is required if any of these symptoms occur during or after treatment.

Patients with a known hypersensitivity to nefopam or any component of the formulation, those currently taking monoamine‑oxidase inhibitors, and individuals with a history of seizures should avoid using Nefopam Medisol unless specifically directed by a physician.